On June 15, 2023, Eloxx Pharmaceuticals Inc made an announcement regarding the final data assessment from the Phase 2 trial of their lead investigational product candidate for cystic fibrosis, ELX-02. The trial tested ELX-02 in combination with ivacaftor with Class 1 Cystic Fibrosis patients. The assessment involved a reanalysis using a change in ppFEV1 from Day 1 instead of baseline. The results showed that ELX-02 demonstrated clinically relevant improvement in ppFEV1, which is a standardized assessment to evaluate lung function. Although the ELX-02 combo was well tolerated, it did not achieve statistical significance for efficacy endpoints.
The final analysis of 13 patients evaluable versus 11 at the time of initial assessment revealed that six of 13 patients entered the trial from the monotherapy arm and had a decrease in lung function (annualized -4.26% reduction in ppFEV1) due to disease progression. However, treatment with ELX-02 stabilized disease overall and resulted in a clinically relevant increase in ppFEV1 in six of thirteen patients based on a change in ppFEV1 at the end of treatment at Day 35 compared to the start of treatment at Day 1. Topline data previously confirmed biological activity, and patients with higher baseline sweat chloride levels had increased responses to treatment as indicated by sweat chloride concentration.
The trial showed that ELX-02 was generally well tolerated without any treatment-related serious adverse events. Cystic fibrosis is a genetic disorder that affects the lungs and other organs, causing difficulty breathing and other symptoms. There are several medical treatments available for cystic fibrosis that may improve lung function, clear mucus from the airways, and prevent mucus from building up in the lungs. While ELX-02 demonstrated clinically relevant improvement in ppFEV1, it did not achieve statistical significance for efficacy endpoints.
Eloxx Pharmaceuticals, Inc.
ELOX
Neutral
Updated on: 15/06/2023
Social Sentiments
8:00 PM (UTC)
Date:15 June, 2023
0
Twitter Sentiment
0.7
Stocktwits Sentiment
Analyst Ratings
There are no analysts data to display
ELOX Stock Shows Positive Earnings Growth in Health Technology and Biotechnology Industry
On June 15, 2023, ELOX stock opened at $7.58, higher than its previous close of $6.98. The day’s range was between $6.31 and $7.58, with a volume of 3,266 shares traded. The market cap for ELOX was $12.8M.
Earnings growth for ELOX was positive, with a growth rate of 56.36% for the last year and 49.85% for this year. In terms of sector and industry, ELOX belongs to Health Technology and Biotechnology, respectively.
Compared to other companies in the same industry, ELOX’s performance was mixed. ELOX’s next reporting date is on August 9, 2023, with an EPS forecast of -$1.55.
Investors should continue to monitor the company’s financials and industry trends to make informed investment decisions.
Eloxx Pharmaceuticals Inc (ELOX) Target Price Forecasted at $50.00 – Potential Increase of 691.14%
On June 15, 2023, Eloxx Pharmaceuticals Inc (ELOX) had a median target price forecast of $50.00, with a high estimate and a low estimate also at $50.00. This represents a significant increase of 691.14% from the last price of $6.32. The consensus among one polled investment analyst is to buy the stock in Eloxx Pharmaceuticals Inc, which has remained unchanged since January.
